134441-93-3

Usage

Uses

Used in Organic Synthesis:
(S)-2-Hydroxymethyl-piperidine-1-carboxylic acid tert-butyl ester is used as a reagent in organic synthesis for its ability to undergo various synthetic transformations. The tert-butyl ester group allows for selective reactions while protecting the carboxylic acid, making it a versatile building block in the synthesis of complex organic molecules.
Used in Pharmaceutical Research:
In the pharmaceutical industry, (S)-2-Hydroxymethyl-piperidine-1-carboxylic acid tert-butyl ester is used as a valuable building block for the construction of bioactive molecules and pharmaceutical intermediates. Its chiral nature and functional groups make it suitable for the development of new drugs and drug candidates with potential therapeutic applications.
Used in Drug Synthesis:
(S)-2-Hydroxymethyl-piperidine-1-carboxylic acid tert-butyl ester is used as a key intermediate in the synthesis of various pharmaceutical compounds. Its unique structure and functional groups enable the creation of novel drug molecules with specific biological activities, contributing to the advancement of medicinal chemistry and drug discovery.

InChI:InChI=1/C11H21NO3/c1-11(2,3)15-10(14)12-7-5-4-6-9(12)8-13/h9,13H,4-8H2,1-3H3/t9-/m0/s1

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 596129-26-9 (S)-1-(2,2,2-Trifluoro-acetyl)-piperidine-2-carboxylic acid (S)-3,4,4-trimethyl-2-oxo-tetrahydro-furan-3-yl ester 
• 26250-84-0 (S)-(-)-1-(tert-butoxycarbonyl)-2-piperidinecarboxylic acid 
• 35677-83-9 methyl (S)-pipecolinate 
• 200184-53-8 (S)-1-tert-butyl 2-methyl piperidine-1,2-dicarboxylate 
• 150521-32-7 (S)-1-N-Boc-piperidine-2-al 
• 41373-39-1 (S)-pipecolinol 
• 1239315-62-8 tert-butyl (2S)-2-[(tert-butyldimethylsilyloxy)methyl]piperidine-1-carboxylate 
• 1201635-96-2 (S)-tert-butyl-6-(benzyloxymethyl)-5,6-dihydropyridine-1(2H)-carboxylate 
• 3105-95-1 pipecolinic acid 
• 116611-45-1 (2R)-2-t-butoxycarbonylamino-3-phenylsulfonyl-1-(2-tetrahydropyranyloxy)propane 
• 3433-37-2 piperidin-2-ylmethanol 
• 259133-67-0 2-carboxy-N-Boc-1,4,5,6-tetrahydropyridine 
• 146337-23-7 tert-butyl 3-methoxypiperidine-1-carboxylate 

Downstream Products

• 197142-43-1 2-(tert-butyl-diphenylsilanyloxymethyl)-6-oxo-piperidine-1-carboxylic acid tert-butyl ester 
• 1214914-34-7 (S)-2-(2-oxo-propyl)-piperidine-1-carboxylic acid tert-butyl ester 
• 3105-95-1 pipecolinic acid 
• 639458-43-8 (S)-2-(2-oxo-ethyl)-piperidine-1-carboxylic acid tert-butyl ester 
• 929917-69-1 (S)-(+)-piperidine-2-methanol hydrochloride 
• 139894-04-5 hexahydro-indolizin-3-one 
• 18881-13-5 (+)-coniceine 
• 259133-72-7 (2R,6R)-2-Phenoxythiocarbonyloxymethyl-6-propyl-piperidine-1-carboxylic acid tert-butyl ester 
• 393827-07-1 (S)-2-vinyl-piperidine-1-carboxylic acid tert-butyl ester 

Relevant academic research and scientific papers

A short enantioselective total synthesis of (R)- and (S)-pipecolic acid

A convenient and practical total synthesis of (R)- and (S)-pipecolic acid has been achieved by utilizing chiral cis-aziridine-2-carboxylate as the common synthetic precursor. The synthesis involves regioselective reductive cleavage of the aziridine ring and Wittig olefination as key reactions.

X-ray Structure-Guided Discovery of a Potent, Orally Bioavailable, Dual Human Indoleamine/Tryptophan 2,3-Dioxygenase (hIDO/hTDO) Inhibitor That Shows Activity in a Mouse Model of Parkinson’s Disease

Human indoleamine 2,3-dioxygenase 1 (hIDO1) and tryptophan 2,3-dioxygenase (hTDO) have been closely linked to the pathogenesis of Parkinson’s disease (PD); nevertheless, development of dual hIDO1 and hTDO inhibitors to evaluate their potential efficacy against PD is still lacking. Here, we report biochemical, biophysical, and computational analyses revealing that 1H-indazole-4-amines inhibit both hIDO1 and hTDO by a mechanism involving direct coordination with the heme ferrous and ferric states. Crystal structure-guided optimization led to23, which manifested IC50values of 0.64 and 0.04 μM to hIDO1 and hTDO, respectively, and had good pharmacokinetic properties and brain penetration in mice.23showed efficacy against the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced mouse motor coordination deficits, comparable to Madopar, an anti-PD medicine. Further studies revealed that different from Madopar,23likely has specific anti-PD mechanisms involving lowering IDO1 expression, alleviating dopaminergic neurodegeneration, reducing inflammatory cytokines and quinolinic acid in mouse brain, and increasing kynurenic acid in mouse blood.

PRODRUG COMPOUNDS

Disclosed are compounds of Formula (I), Formula (II), Formula (III), and Formula (IV): or salts thereof, wherein R1, R2, R3, and R4 are defined herein. Also disclosed are methods of using the compounds as prodru

COMPOUNDS, COMPOSITIONS AND METHODS FOR SYNTHESIS

The present disclosure, among other things, provides technologies for synthesis, including reagents and methods for stereoselective synthesis. In some embodiments, the present disclosure provides compounds useful as chiral auxiliaries. In some embodiments, the present disclosure provides reagents and methods for oligonucleotide synthesis. In some embodiments, the present disclosure provides reagents and methods for chirally controlled preparation of oligonucleotides. In some embodiments, technologies of the present disclosure are particularly useful for constructing challenging internucleotidic linkages, providing high yields and stereoselectivity.

As hepatitis c inhibitor spiro compound and its use in medicine

The invention provides a spiro compound serving as a hepatitis c inhibitor and application thereof in a medicine. The compound is a compound as shown in a formula (I) or a stereisomer, a geometric isomer, a tautomer, nitric oxide, an aquo-complex, a solvate, a metabolite, pharmaceutically acceptable salt or prodrug of the compound as shown in the formula (I). The invention also provides a pharmaceutical composition containing the compound, application of the compound and the pharmaceutical composition in inhibition of HCV (Hepatitis C Virus) copy and HCV virus protein, as well as the application of the compound and the pharmaceutical composition in prevention, handling, treatment or relieving of HCV infection or hepatitis c disease for a patient. The formula I is as shown in the specification.

Benzimidazole-2-piperazine compound, its pharmaceutical composition and its preparation and use

The invention relates to a benzimidazole-2-piperazine derivative and a preparing method and application of the benzimidazole-2-piperazine derivative in medicine, in particular to a novel benzimidazole-2-piperazine derivative shown in the general formula (I), a preparing method of the derivative, a pharmaceutical composition containing the derivative and application of the derivative serving as a therapeutic agent, especially serving as a poly (ADP-ribose) polymerase (PARP) inhibitor. In the general formula (I), R refers to hydrogen or halogen, G refers to carbonyl or methylene, m is 1-2, n is 1-3, and Q refers to hydrogen or C1-C4 alkyl. When X is methylene and Y is NR1 or methylene, X is NR1; R1 refers to hydrogen, C1-C6 alkyl, benzyl, COR2 or SO2R2; R2 refers to the following groups which are not substituted or groups substituted by 1-3 substituent groups, including C1-C6 alkyl, C3-C8 naphthenic base, phenyl, benzyl, naphthyl and C5-C10 aromatic heterocycle base, heterocycle in the C5-C10 aromatic heterocycle base comprises 1-3 heteroatoms selected from N, O and S, and the substituent groups are selected from the following atoms or groups of C1-C6 alkyl, C1-C6 alkoxy, halogen, amidogen, nitryl, sulfydryl, hydroxyl, cyanogroup and trifluoromethyl. The general formula (I) is shown in the specification.

Discovery and Total Synthesis of Streptoaminals: Antimicrobial [5,5]-Spirohemiaminals from the Combined-Culture of Streptomyces nigrescens and Tsukamurella pulmonis

A series of lipidic spirohemiaminals, designated streptoaminals, is reported. These were discovered by surveying the unique molecular signatures identified in the mass spectrometry data of the combined-culture broth of Streptomyces nigrescens HEK616 and T

A strategy for complex dimer formation when biomimicry fails: Total synthesis of ten coccinellid alkaloids

Although dimeric natural products can often be synthesized in the laboratory by directly merging advanced monomers, these approaches sometimes fail, leading instead to non-natural architectures via incorrect unions. Such a situation arose during our studies of the coccinellid alkaloids, when attempts to directly dimerize Natures presumed monomeric precursors in a putative biomimetic sequence afforded only a non-natural analogue through improper regiocontrol. Herein, we outline a unique strategy for dimer formation that obviates these difficulties, one which rapidly constructs the coccinellid dimers psylloborine A and isopsylloborine A through a terminating sequence of two reaction cascades that generate five bonds, five rings, and four stereocenters. In addition, a common synthetic intermediate is identified which allows for the rapid, asymmetric formal or complete total syntheses of eight monomeric members of the class.

SWEET FLAVOR MODIFIER

The present invention includes compounds having structural formula (I), or salts or solvates thereof. These compounds are useful as sweet flavor modifiers. The present invention also includes compositions comprising the present compounds and methods of modulating the sweet taste of compositions.

L-Proline derived nitrogenous steroidal systems: An asymmetric approach to 14-azasteroids

An efficient chiral pool approach using l-proline to access 14-azasteroids under mild reaction conditions has been described. The key step involves the intramolecular SN2′ cyclization reaction for the construction of critical C-ring in the nitrogen impregnated steroidal architectures bearing unsaturation at Δ9(11) position. In the endeavour to synthesize some new congeners, the remote electronic impact of the electron donating groups in A ring and heteroatoms like oxygen in B ring, on the propensity of C-ring cyclization was also observed.